WO2012138100A3 - Ｄｌｋ１ 세포 외 수용성 도메인을 포함하는 액티빈 수용체 타입 2ｂ 억제제 - Google Patents

Ｄｌｋ１ 세포 외 수용성 도메인을 포함하는 액티빈 수용체 타입 2ｂ 억제제 Download PDF

Info

Publication number
WO2012138100A3
WO2012138100A3 PCT/KR2012/002492 KR2012002492W WO2012138100A3 WO 2012138100 A3 WO2012138100 A3 WO 2012138100A3 KR 2012002492 W KR2012002492 W KR 2012002492W WO 2012138100 A3 WO2012138100 A3 WO 2012138100A3
Authority
WO
WIPO (PCT)
Prior art keywords
dlk1
soluble domain
acvr2b
receptor type
receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2012/002492
Other languages
English (en)
French (fr)
Other versions
WO2012138100A2 (ko
Inventor
박영우
조기원
이동희
이은경
장세일
박찬웅
김동진
김혜난
박윤정
박재은
박지현
유석호
장명희
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Korea Research Institute of Bioscience and Biotechnology KRIBB
Antibody and Receptor Therapeutics Co Ltd
Original Assignee
Korea Research Institute of Bioscience and Biotechnology KRIBB
Antibody and Receptor Therapeutics Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR1020120001452A external-priority patent/KR101461706B1/ko
Application filed by Korea Research Institute of Bioscience and Biotechnology KRIBB, Antibody and Receptor Therapeutics Co Ltd filed Critical Korea Research Institute of Bioscience and Biotechnology KRIBB
Priority to US14/009,037 priority Critical patent/US20140072558A1/en
Publication of WO2012138100A2 publication Critical patent/WO2012138100A2/ko
Publication of WO2012138100A3 publication Critical patent/WO2012138100A3/ko
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/485—Epidermal growth factor [EGF], i.e. urogastrone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

본 발명은 DLK1(delta-like 1 homolog)의 세포 외 영역 수용성 도메인을 포함하는 액티빈 수용체 타입 2B 억제제에 관한 것이다. 보다 구체적으로 본 발명은, DLK1의 세포 외 수용성 도메인, DLK1의 세포 외 수용성 도메인의 단편, DLK1의 세포 외 수용성 도메인의 변이체(mutant) 또는 상기 변이체의 단편을 유효성분으로 포함하는, 액티빈 수용체 타입 2B(activin receptor type II B, ACVR2B)와 ACVR2B를 수용체로 가지는 리간드의 결합 억제용 조성물 및 이를 포함하는 질환의 예방 또는 치료용 약학적 조성물 등에 관한 것이다. 본 발명의 조성물은 액티빈 수용체 타입 2B에 결합하는 리간드들과 액티빈 수용체 타입 2B에 경쟁적으로 결합함으로써, 리간드가 상기 수용체에 결합하는 것을 억제하며, 리간드들과 관련된 단백질 신호전달을 억제하는바, 관련 질환의 예방 또는 치료에 유용하게 사용될 수 있다.
PCT/KR2012/002492 2011-04-04 2012-04-03 Ｄｌｋ１ 세포 외 수용성 도메인을 포함하는 액티빈 수용체 타입 2ｂ 억제제 Ceased WO2012138100A2 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US14/009,037 US20140072558A1 (en) 2011-04-04 2012-04-03 Activin Receptor Type II B Inhibitors Comprising DLK1 Extracellular Water-Soluble Domain

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
KR10-2011-0030871 2011-04-04
KR20110030871 2011-04-04
KR10-2012-0001452 2012-01-05
KR1020120001452A KR101461706B1 (ko) 2011-04-04 2012-01-05 Ｄｌｋ１ 세포 외 수용성 도메인을 포함하는 액티빈 수용체 타입 2ｂ 억제제

Publications (2)

Publication Number Publication Date
WO2012138100A2 WO2012138100A2 (ko) 2012-10-11
WO2012138100A3 true WO2012138100A3 (ko) 2013-01-10

Family

ID=46969662

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2012/002492 Ceased WO2012138100A2 (ko) 2011-04-04 2012-04-03 Ｄｌｋ１ 세포 외 수용성 도메인을 포함하는 액티빈 수용체 타입 2ｂ 억제제

Country Status (1)

Country Link
WO (1) WO2012138100A2 (ko)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005052156A1 (ja) * 2003-11-28 2005-06-09 Kanagawa Academy Of Science And Technology 肝癌の検出方法及び肝癌診断薬並びに癌治療薬
KR20090088893A (ko) * 2006-11-10 2009-08-20 가부시키가이샤 리부텍쿠 ｉｎ ｖｉｖｏ 에서 항종양 활성을 갖는 항인간 Ｄｌｋ－１ 항체
KR100982170B1 (ko) * 2010-03-16 2010-09-15 한국생명공학연구원 ＤＬＫ１―Ｆｃ 융합 단백질을 유효성분으로 함유하는 암 전이 억제용 조성물

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005052156A1 (ja) * 2003-11-28 2005-06-09 Kanagawa Academy Of Science And Technology 肝癌の検出方法及び肝癌診断薬並びに癌治療薬
KR20090088893A (ko) * 2006-11-10 2009-08-20 가부시키가이샤 리부텍쿠 ｉｎ ｖｉｖｏ 에서 항종양 활성을 갖는 항인간 Ｄｌｋ－１ 항체
KR100982170B1 (ko) * 2010-03-16 2010-09-15 한국생명공학연구원 ＤＬＫ１―Ｆｃ 융합 단백질을 유효성분으로 함유하는 암 전이 억제용 조성물

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KICHOON LEE ET AL.: "Inhibition of adipogenesis and development of glucose intolerance by soluble preadipocyte factor-1 (Pref-1)", THE JOURNAL OF CLINICAL INVESTIGATION, vol. 111, no. 4, 2003, pages 453 - 461 *

Also Published As

Publication number Publication date
WO2012138100A2 (ko) 2012-10-11

Similar Documents

Publication Publication Date Title
WO2010005566A3 (en) Notch-binding agents and antagonists and methods of use thereof
PH12018502038A1 (en) Novel antibodies inhibiting c-met dimerization, and uses thereof
WO2009129246A3 (en) Compositions and methods for preparing and using same
WO2008039390A3 (en) Compositions and methods for chitosan enhanced immune response
WO2018091740A3 (en) Novel anti_cd137 antibodies and uses thereof
WO2010003992A8 (en) Combination of a c-met antagonist and an aminoheteroaryl compound for the treatment of cancer
WO2010136311A3 (en) Compositions and methods for antibodies targeting complement protein c3b
WO2008091641A3 (en) Compositions and methods for diagnosing and treating cancer
MY151191A (en) Novel antibodies
WO2011003557A8 (en) A complex of bi-specific antibody and digoxigenin conjugated to a therapeutic or diagnostic agent
MY195289A (en) Anti IL-36R Antibodies
WO2009142738A3 (en) Compositions and methods for diagnosing and treating cancer
WO2008047243A3 (en) Pharmaceutical composition for suppression of apoptosis and method for delivering the same
WO2009002947A3 (en) Compounds and peptides that bind the trail receptor
WO2012107416A3 (en) Improved immunotherapy
UA102867C2 (uk) Антитіла до cxcr4 та їх застосування у лікуванні раку
HK1250737A1 (zh) 结合cd79的抗体分子
WO2011112867A8 (en) The use of fenoterol and fenoterol analogues in the treatment of glioblastomas and astrocytomas
WO2011003100A3 (en) Compositions and methods for diagnosing and/or treating influenza infection
EP4678660A3 (en) Antibody against activin receptor type ii receptor for use in treating heart failure
WO2011116212A3 (en) Bone morphogenetic protein receptor binding agents and methods of their use
WO2010011952A3 (en) Flip death effector domain derived peptides for inducing autophagy
WO2009114461A3 (en) Angiotensin (1-7) dosage forms and uses thereof
CA3076691A1 (en) Anti-adrenomedullin (adm) binder for use in therapy or prevention of symptoms of illness
WO2009047513A3 (en) Antagonists of kisspeptin and uses thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12768571

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 14009037

Country of ref document: US

122 Ep: pct application non-entry in european phase

Ref document number: 12768571

Country of ref document: EP

Kind code of ref document: A2